Leonid 1st December event press review "Corriere Adriatico"

Press Review "LEONID: un innovativo dispositivo medico per un'analisi più veloce e certa al polmone"

Press Review "Diatech: dispositivo medico per analisi rapida tumore al polmone"

Leonid 1st December event press review "TGR Un kit per la cura mirata dei tumori"

Leonid final event December 1st

Title of the event Leonid:

Leonid EU opportunities, Italian success – A revolutionary diagnostic device for lung cancer

The event was held at the headquarters of the Diatech Pharmacogenetics. guests who attended the event were:

• Genetic Lab management:
• Cristina LaPucci Geneticist and Director of Laboratory Genetic Lab
• Alessandro Sbicego Vice Director of Laboratory Genetic Lab
• BiMind  management
• Marco Marinelli Sales Manager BiMind
• Maurizio Vico  Software Design and Development Manager
• BiMind Staff three employees
• Mauro Magnani Professor from the University Carlo Bo, Urbino
• Professors from the University Politecnica delle Marche, Ancona  
• Professors from Milan Politecnico University, Milan
• Professors from the IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura del Cancro, Meldola
• Professors from the department of the phatology laboratory of Azienda Ospedaliero Universitaria of Pisa
• Main delegates from Ospedali Riuniti di Ancona, the most important hospital of the Marche region.
• Michele Caporossi General Manager Ospedali Riuniti di Ancona
• Diatech Pharmacogenetics clients
• Some exponent from the companies in the Diatech’s area district (Marche Region)
• Troupe television TG3 RAI
• Journalists 

PROGRAM OF THE DAY

10:00 Welcome to Diatech!
Hall, 2° floor

11:00 Presentation of the results of the project LEONID
Auditorium, 2° floor

Welcome greetings

Fabio Biondi - Diatech Pharmacogenetics  President

Luca Ceriscioli - President of Regione Marche

Mariangela Siler DG research and innovation in Health, Ministry of Health

Manuela Bora  Productive Activities of the Marche Region - Regional policies in the health field

Nicoletta Amodio Manager Research and Innovation, Confindustria

12:10 The history and the results of the project LEONID - Maura Menghi Scientific Director Diatech Pharmacogenetics

12:30 LEONID clinical study: presentation of preliminary results - Paola Ulivi Settore Biomarcatori e Medicina Personalizzata- Diagnostica molecolare III livello, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) IRCCS Meldola

12:45 Myriapod® Lung Fusion Genes in the clinical practice  - Gabriella Fontanini Dipartimento di Patologia Medica Molecolare e di Area Critica, University of Pisa

13:00 Networking lunch, 2° floor

Here some photos of the event:

Welcome greetings by Fabio Biondi

Mariangela Siler - Ministry of Health

Gabriella Fontanini during the interview

Networking lunch

Networking lunch

People at work at Nanostring platform

Diatech Pharmacogenetics’ team

Leonid EU opportunities Italian success A revolutionary diagnostic device for lung cancer - Download program

LEONID Lung cancEr fusiOn geNes: a new dIagnostic Device

Leonid EU opportunities Italian success - A revolutionary diagnostic device for lung cancer

PROGRAM FINAL EVENT 

10:00 Welcome to Diatech!
Hall, 2° flor

11:00 Presentation of the results of the project LEONID
Auditorium, 2° flor

Welcome greetings

Fabio Biondi - Diatech Pharmacogenetics  President

Luca Ceriscioli - President of Regione Marche Mariangela Siler DG research and innovation in Health, Ministry of Health

11:30 Regional policies in the health field - Manuela Bora  Productive Activities of the Marche Region

11:50 Italian companies in European and national programs for R&I - Nicoletta Amodio Manager Research and Innovation, Confindustria

12:10 The history and the results of the project LEONID - Maura Menghi Scientific Director Diatech Pharmacogenetics

12:30 LEONID clinical study: presentation of preliminary results - Paola Ulivi Settore Biomarcatori e Medicina Personalizzata- Diagnostica molecolare III livello, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) IRCCS Meldola

12:45 Myriapod® Lung Fusion Genes in the clinical practice  - Gabriella Fontanini Dipartimento di Patologia Medica Molecolare e di Area Critica, University of Pisa

13:00 Networking lunch, 2° flor

Leonid Save the Date Final Event December 1st 2016

Download Leonid brochure

XVIII CONGRESSO NAZIONALE AIOM - ROMA, October 28th-30th 2016

Leonid’s product and impacts

• RealQuant® Lung Fusion Genes, medical device validated for in vitro diagnostic use under the 98/79/EC directive.
• One test for multiple biomarkers detection and quantification (ALK, ROS1 and RET gene rearrangements in the same reaction) --> reduction of costs.
• Identification of the main fusion genes in the same well.
• Standardized results without personal interpretation and simplification of the medical report thanks to a dedicated software for secondary analysis on Nanostring® output data --> reduction of data decoding errors.
• Easy-of-use (only 4 pipetting steps) --> reduction of hands-on-time and manual errors. 
• Higher throughput (up to 10 samples per run).
• Faster workflow (from FFPE tissue to data in less than 2 days).
• Quality control of pre-analytical and analytical steps.
• Performance validated in a multicenter clinical study at Dipartimento di Patologia Chirurgica, Medica, Molecolare e dell'Area Critica, Università di Pisa - Azienda Ospedaliero Universitaria Pisana (Pisa) and at Laboratorio di Bioscienze, Diagnostica Molecolare di III livello - Biomarcatori e Medicina Personalizzata, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) IRCCS (Meldola). 

Horizon 2020 programma quadro in ricerca e innovazione: le varie opportunità per la salute, cenni alla progettazione e confronto tra le esperienze pubblico - private  

Rome 14th July Ministry of Health Auditorium, Viale Giorgio Ribotta 5, Rome

Maura Menghi Diatech Pharmacogenetics Scientific Directors and IRCSS Meldola Staff take part in session number 3:

Esperienze vincenti in Horizon 2020: il valore della collaborazione tra pubblico e privato

• Fabrizia Lattanzio, INRCA, Progetto Scop

• Marina Cuttini, Ospedale Pediatrico Bambino Gesù, SHIPS

• Marco Molinari, Fondazione Santa Lucia, Progetto NISCI

• Costantino Bongiorno, WeMake, Progetto Opencare

• Evert Jan Hoogerwerf, AIAS, Progetto ProACT (contributo video)

• Maura Menghi, Diatech Pharmacogenetics, Progetto LEONID

• Michele Nicoletta, ABBVIE

• Sigma-tau (tbc)    

Press Review "Terapie su Misura" Business People